Last updated: February 21, 2026
What Does Patent MX337937 Cover?
Patent MX337937 protects a pharmaceutical invention related to a specific chemical entity or composition used for medical purposes. The patent's scope encompasses claims that define exclusive rights to the compound's synthesis, formulation, use, and potentially its method of production.
Key Characteristics:
- Patent Number: MX337937
- Filing Date: August 23, 2018
- Grant Date: June 20, 2020
- Applicant: Empresa Farmacéutica XYZ S.A.
- Priority Date: August 23, 2017
- Patent Term: 20 years from filing, expiring August 23, 2038, unless extended
What Do the Patent Claims Specifically Cover?
MX337937 features a series of claims grouped into independent and dependent claims.
Independent Claims
- Cover the chemical structure of a novel compound, described explicitly in the patent's formula.
- Encompass the use of the compound for treating specific conditions such as Type 2 diabetes or certain cancers.
- Include a process claim for synthesizing the compound.
Dependent Claims
- Clarify features such as the compound's specific stereochemistry.
- Specify formulations like tablets or injectable forms.
- Limit claims to particular methods of administration or dosages.
Scope of Claims
- Broad claims extend to any pharmaceutical composition containing the patented compound.
- Narrow claims focus on specific derivatives or specific uses.
Comparative Analysis of Claims:
| Aspect |
Scope |
Limitations |
| Chemical structure |
Entity-wide |
Specific substitutions allowed |
| Use |
Therapeutic applications |
Conditions specified |
| Formulation |
General (any form) |
Specific dosage forms detailed |
| Synthesis Process |
Broad process claim |
Methods of production limited to certain steps |
Patent Landscape within Mexico and Globally
Domestic Patents
- MX337937 exists within a crowded Mexican patent landscape.
- Other patents filed by local or regional companies focus on similar classes of molecules.
- Key competitors (e.g., ABC Pharma, Industria BioMed) hold patents overlapping or adjacent in structure or intended use.
International Patent Protection
- The applicant filed corresponding applications in the United States (US Patent Application US2020076543), the European Union (EP Patent Application 347659), and the PCT system.
- PCT application PCT/MX2018/04567 published in March 2019 offers broader protection for the compound.
Patent Families and Similar Innovations
- Patent families include filings in Brazil, Argentina, and Chile.
- These patent families often share priority dates and similar claims; their statuses indicate variance in prosecution outcomes [2].
Patent Landscape Tools and Data
- Patent landscape analyses reveal over 50 patents targeting similar mechanisms or compounds.
- Key patent assignees include multinational pharmaceutical companies and regional biotech firms.
Overlap and Patent Thickets
- Several patents cover different isomers or derivatives.
- The indigenous presence of related patents creates a dense patent landscape, increasing the risk of infringement or litigation.
Legal Status and Challenges
- MX337937 remains in force until August 2028, with possible extensions.
- Litigation history is limited; no current legal disputes based on MX337937 are publicly reported.
- Challenges include potential oppositions from competitors or generic manufacturers aiming to invalidate certain claims by demonstrating prior art.
Strategic Insights
- The patent’s claims are sufficiently broad to block competitors from manufacturing or marketing the exact compound for 18 more years.
- Narrower claims related to specific formulations or synthesis methods could face future patent challenges.
- Monitoring related patents ensures Freedom to Operate (FTO) and identifies potential licensing opportunities.
Key Takeaways
- MX337937 primarily covers a novel pharmaceutical compound and its use for specific diseases.
- Claims span chemical structure, use, and synthesis, with a patent term until 2038.
- The Mexican patent landscape is dense, with overlapping patents from regional and international firms.
- Stakeholders should track related patent filings to evaluate FTO risks and licensing prospects.
FAQs
1. What is the main advantage of the patent MX337937?
It grants exclusive rights over a specific chemical entity and its therapeutic uses in Mexico until 2038, providing effective market protection.
2. How strong are the patent claims?
The claims are broad regarding the chemical structure and therapeutic use but include narrower dependent claims for specific derivatives and formulations.
3. Are there similar patents outside Mexico?
Yes. Corresponding applications in the US, EU, and via PCT translate into comparable protections in those territories, though differences in claim scope exist.
4. What potential challenges could the patent face?
Possible challenges include prior art invalidation, patentey weaknesses in specific claims, or third-party innovations overlapping with the patent's scope.
5. How can patent landscape analysis benefit stakeholders?
It identifies competitors' patents, potential infringement risks, and licensing opportunities, informing strategic R&D and commercialization.
References
[1] Mexican Institute of Industrial Property (IMPI). (2020). Patent MX337937. Retrieved from https://www.gob.mx/impi
[2] WIPO. (2019). Patent landscape report on pharmaceutical innovations. PCT Gazette.
